Europe Renal Denervation Devices Market - Growth, Trends, and Forecast (2022 - 2027)

The Europe Renal Denervation Devices Market is segmented By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based), and Geography.

Market Snapshot

Europe Renal Denervation Devices
Study Period: 2017-2025
Base Year: 2021
CAGR: 5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Europe Renal Denervation Devices Market is expected to register a CAGR of 5% during the forecast period. The major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure. High blood pressure is called hypertension. The prevalence of hypertension has been observing a significant rise, over the past few years. Generally, blood pressure rises and falls throughout the day, but it can damage one’s heart and result in health problems if hypertension stays high for a long time. The prevalence of hypertension in Germany (55%) is twice as high as in Canada and the United States. According to an article of Samuel Muli published in 2020, the prevalence of hypertension (≥140/90 mmHg) was 73.8%, representing 74.8% in men, and 73.5% in women per 1000 population. The heavy burden of hypertension is expected to drive the market growth during the forecast period.

Moreover, There are significantly more renal denervation devices, which have received CE approval, in the region. As per the, Abbott Medical Devices completed the observational study of the EnligHTN renal denervation system in Europe, in February 2019.

Scope of the report

As per the scope of this report, renal denervation devices are one of several innovative device-based interventional therapies, which help to control blood pressure. It is safe, minimally invasive, and does not leave any implants behind. The market studied is segmented by technology and geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Ultrasound-based Segment is Expected to be the Fastest Growing Segment

The ultrasound-based renal denervation devices are a minimally invasive procedure, using ultrasound to ablate nerves in the wall of the renal arteries, and it disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. Additionally, according to the first randomized trial to compare the techniques (RADIOSOUND-HTN trial), the ultrasound-based renal denervation (RDN) approach has led to greater reductions in blood pressure than radiofrequency ablation in patients, with resistant hypertension. The rising prevalence of hypertension is expected to boost the overall growth of the market studied.

Recor Medical's Paradise Renal Denervation System is one of the commonly used ultrasound device. It is approved in European markets and under trials for FDA approval. According to the European Society of Cardiology’s comparative study of trials, Radiance-HTN Solo (ultrasound-based device- Paradise) showed more efficacy than the radiofrequency based SPYRAL HTN-OFF MED trial device. The device Paradise reduced -6.3 mmHg in daytime ambulatory BP and of -6.5 mmHg in office systolic BP compared to the sham group. The high efficacy of ultrasound-based devices proven in the trials is expected to increase the importance of these devices and revive them.

New Key trend Europe renal.png

Competitive Landscape

The Europe Renal Denervation Devices Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Medtronic PLC, Boston Scientific Corporation , St. Jude Medical Inc., ReCor Medical Inc.,Ablative Solutions Inc., Mercator MedSystems, Terumo Corporation, Symple Surgical

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Hypertension

      2. 4.2.2 Long Lasting Effect of the Procedure

    3. 4.3 Market Restraints

      1. 4.3.1 Painful Procedure

      2. 4.3.2 Stringent Approval Process for Renal Denervation Devices and Reimbursement Systems

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Technology

      1. 5.1.1 Radiofrequency-based

      2. 5.1.2 Ultrasound-based

      3. 5.1.3 Micro-infusion-based

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico


    1. 6.1 Company Profiles

      1. 6.1.1 Medtronic PLC

      2. 6.1.2 St. Jude Medical Inc.

      3. 6.1.3 ReCor Medical Inc.

      4. 6.1.4 Ablative Solutions Inc.

      5. 6.1.5 Mercator MedSystems

      6. 6.1.6 Terumo Corporation

      7. 6.1.7 Symple Surgical

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Europe Renal Denervation Devices Market market is studied from 2017 - 2025.

The Europe Renal Denervation Devices Market is growing at a CAGR of 5% over the next 5 years.

Boston Scientific Corporation , Medtronic PLC, St. Jude Medical Inc., ReCor Medical Inc., Ablative Solutions Inc. are the major companies operating in Europe Renal Denervation Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!